Astra Invests $309 Mill On R&D Facilities
Swedish pharmaceutical company Astra has announced plans to invest 2.4billion Swedish kroner ($309.4 million) in research facilities in Sweden, the USA and the UK.
The new facility to be built at Sodertalje, near Stockholm, at a cost of 1.2 billion kroner, will house Astra Pain Control, while 600 million kroner has been set aside for the first stage of a new site in Boston, Massachusetts, where the group's research on the peptic ulcer bacterium, Heliobacter pylori, will be centered.
Astra has also earmarked 600 million kroner for the expansion of its facility in Loughborough, England, to include a laboratory for pharmaceutical development. Meantime, the group's Astra Arcus research unit is to continue reducing its number of operating sites, and the facility in Rochester, New York, will be closed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze